Microalbumin creatinine ratio- Spot Urine

Kidney

Report in 4Hrs

At Home

No Fasting Required

Details

Key marker of kidney filtration function (GFR); elevated in renal impairment.

₹499₹800

38% OFF

Microalbumin Creatinine Ratio - Spot Urine Test Guide

Why is it done?
- Detects small amounts of albumin protein in urine, which may indicate early kidney damage or disease
- Screens for diabetic nephropathy in patients with Type 1 or Type 2 diabetes mellitus
- Monitors kidney function in hypertensive patients or those with chronic kidney disease
- Identifies patients at risk for progressive renal disease and cardiovascular complications
- Provides early detection of kidney injury before clinical proteinuria develops
- Performed routinely as part of diabetes management and nephropathy screening programs
Normal Range
- Normal Result: Less than 30 mg/g creatinine (or less than 3 mg/mmol creatinine)
- Microalbuminuria (Early Stage): 30-300 mg/g creatinine (or 3-30 mg/mmol creatinine)
- Proteinuria (Advanced Stage): Greater than 300 mg/g creatinine (or greater than 30 mg/mmol creatinine)
- Units of Measurement: mg/g creatinine or mg/mmol creatinine (milligrams of albumin per gram or millimole of creatinine)
- Interpretation: Results below 30 mg/g creatinine are considered normal and indicate absence of clinically significant albuminuria. The ratio corrects for urine concentration variations between individuals and accounts for hydration status.
Interpretation
- Less than 30 mg/g Creatinine (Normal): No clinically significant albuminuria; kidney function is normal; no evidence of glomerular damage
- 30-300 mg/g Creatinine (Microalbuminuria): Indicates early kidney disease or early diabetic nephropathy; increased risk of progression to overt proteinuria; marker of endothelial dysfunction and cardiovascular risk; requires intervention and close monitoring
- Greater than 300 mg/g Creatinine (Proteinuria): Indicates advanced kidney disease or overt diabetic nephropathy; significant glomerular damage; high risk for progressive renal failure; associated with increased cardiovascular morbidity and mortality
- Factors Affecting Results: Acute infections or fever may transiently elevate albuminuria; intense physical exercise can increase urinary albumin; menstruation may affect results; dehydration concentrates urine affecting ratios; some medications (ACE inhibitors, ARBs) may lower albuminuria; poor glycemic control in diabetes increases albuminuria
- Clinical Significance: Microalbuminuria is an independent risk marker for cardiovascular disease, hypertension, and progression to end-stage renal disease. It represents a critical window for therapeutic intervention to prevent kidney disease progression and reduce cardiovascular risk through aggressive blood pressure control, glycemic management, and renoprotective medications.
Associated Organs
- Primary Organs: Kidneys (specifically the glomeruli - filtering units); urinary tract including bladder and urethra
- Associated Conditions Detected: Diabetic nephropathy (diabetes-related kidney disease); hypertensive nephropathy (high blood pressure-related kidney damage); chronic glomerulonephritis; focal segmental glomerulosclerosis (FSGS); lupus nephritis; immunoglobulin A nephropathy; end-stage renal disease; acute kidney injury with proteinuria
- Secondary Effects on Other Systems: Microalbuminuria indicates endothelial dysfunction affecting the cardiovascular system; associated with increased risk of myocardial infarction and stroke; related to vascular damage in the retina (diabetic retinopathy); involved in pathophysiology of metabolic syndrome
- Potential Complications: Progressive decline in glomerular filtration rate (GFR); development of overt proteinuria; progression to chronic kidney disease stages 3-5; end-stage renal disease requiring dialysis or transplantation; fluid retention and hypertension; electrolyte imbalances; cardiovascular events and mortality
Follow-up Tests
- Recommended Follow-up Tests: Serum creatinine and estimated glomerular filtration rate (eGFR); blood urea nitrogen (BUN); comprehensive metabolic panel including electrolytes and glucose; fasting blood glucose or HbA1c for diabetes assessment; lipid panel; blood pressure monitoring
- Confirmatory Tests: 24-hour urine protein collection; repeat spot urine microalbumin creatinine ratio to confirm persistent albuminuria; urinalysis with microscopy; urine electrophoresis if indicated
- Imaging Studies: Renal ultrasound to assess kidney size and exclude structural abnormalities; CT scan if complex kidney disease suspected
- Specialized Testing: Kidney biopsy if diagnosis is unclear or atypical presentation; serological testing (ANA, complement levels, ANCA) if autoimmune nephritis suspected
- Monitoring Frequency: Annually for diabetic patients without albuminuria; every 6-12 months for those with microalbuminuria; every 3-6 months if proteinuria is present; more frequently if kidney function is declining; baseline and periodic testing for hypertensive patients at risk
- Complementary Markers: Cystatin C (alternative GFR marker); neutrophil gelatinase-associated lipocalin (NGAL) for acute kidney injury; fibroblast growth factor 23 (FGF-23) if phosphate metabolism abnormality suspected
Fasting Required?
- Fasting Requirement: No
- Patient Preparation: Fasting is not necessary for this test; patient may eat and drink normally before collection
- Collection Instructions: Collect a random spot urine sample (preferably first morning void for consistency); use sterile container provided; collect approximately 30-50 mL; avoid contamination from external sources; women should clean the genital area before collection
- Factors to Avoid: Avoid intense physical exercise 24 hours before collection as it may temporarily elevate albumin; avoid collection during menstruation; postpone test if patient has acute infection or fever; discontinue medications only if specifically instructed by physician (ACE inhibitors and ARBs should generally be continued)
- Special Considerations: Adequate hydration status is important; maintain normal fluid intake; if borderline results obtained, repeat testing after 1-2 weeks to confirm findings; ensure proper specimen labeling and timely transport to laboratory

How our test process works!